Kidney Disease & Nephrology Clinical Trials Update: Week 13, 2026

Published March 29, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

This large Phase 3 trial involved more than 1700 adults with advanced chronic kidney disease, including those on dialysis, who are at high risk for heart problems. The study tested whether low doses of rivaroxaban, an oral blood thinner, could reduce serious heart-related events in this vulnerable group. If the results are positive, this could become an important new option to help protect heart health in people with severe kidney disease.

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

This ongoing international Phase 3 trial is exploring the combination of two medications, baxdrostat and dapagliflozin, in adults with chronic kidney disease and high blood pressure. The goal is to find a treatment that better preserves kidney function and lowers the risk of heart problems. The trial’s broad eligibility means many patients may be able to participate and benefit from this research.

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

This Phase 3 study is testing a new cell therapy called REACT for adults who have both type 2 diabetes and chronic kidney disease. This approach aims to slow down kidney damage and improve overall health outcomes. Recruiting is underway across many sites worldwide, making the study accessible to a wide range of patients living with these conditions.

Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

This trial is investigating sotagliflozin, an oral medication, to see if it can slow the loss of kidney function in people with type 1 diabetes and diabetic kidney disease. Conducted in the United States and Canada, the study plans to enroll 150 participants and follow them for several years. Positive findings could lead to new ways to protect kidney health and reduce complications in this group.

Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric AKI

This study focuses on critically ill children with acute kidney injury who are receiving kidney support treatments in pediatric intensive care units. Researchers are testing a biomarker called NGAL to help guide fluid management and the timing of kidney replacement therapy. If successful, this could improve how doctors care for these vulnerable children and potentially lead to better recovery outcomes.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.